ABBV-453
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for ABBV-453, covering 2025-08-14 to 2026-02-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) [Phase 1, Phase 2]